Compare Inovio Pharmaceuticals Inc (INO) vs ServiceNow Inc (NOW) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

ServiceNow (NOW) trades at $103.24, down 0.74% today, with a bearish technical signal but strong fundamentals including 76.56% gross margins and consistent revenue growth to $13.28B in 2025. The stock shows robust cash flow generation of $5.44B from operations and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth opportunities and conference presentations.

Outlook remains positive with an 85.51% analyst buy rating and $135.14 consensus price target, suggesting 31% upside. Key risks include high valuation multiples (P/E 62.32) and competitive pressures in enterprise software. Earnings execution and AI adoption present the primary catalysts for continued appreciation.